Glaxo receives FDA 'complete response' for cervical cancer vaccine

Dec 17 2007 - 8:24am

GlaxoSmithKline (NYSE: GSK) announced today that it has received a complete response letter from the U.S. Food and Drug Administration related to its application for the cervical cancer vaccine, CERVARIX

Share this content.

Contact Us To Be Mentioned in